Biocon shares surged after global pharma major Mylan Inc, and the Indian pharma company confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, in comparison to Roche's bra
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms...
Maruti Suzuki shares closed 2.94 per cent down at Rs 3748.45 after Japense yen soared almost 3 per cent against the dollar and euro as the Bank of Japan opted out of any further moves to ease policy.
Biotechnology major Biocon today reported 79 per cent jump in consolidated net profit at Rs360.9 crore for the
fourth quarter ended March 31, 2016, on the back of exceptional income and robust sales.
Biotechnology firm Biocon reported a 79.1 per cent increase in its net profit at Rs 360.9 crore for the fourth quarter ended March on top of higher sales and exceptional income.
Biocon Inc, part of biotechnology major Biocon, is recalling in the US 5,505 bottles of cholesterol lowering Simvastatin tablets for being sub-potent, according to the USFDA.
Labelling government's thrust on manufacturing sector as mere "lip service", Biocon chief Kiran Mazumdar-Shaw has said that ease of doing business in India has not improved...
The approval will enable the company to address $1.2 billion opportunity, starting FY17 Biocon has received European approvals for its Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor
Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third quarter ended December 31, 2015-16.
